Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$10.14 - $12.38 $402,558 - $491,486
-39,700 Reduced 4.15%
916,314 $9.49 Million
Q2 2022

Aug 15, 2022

BUY
$11.05 - $12.72 $290,615 - $334,536
26,300 Added 2.83%
956,014 $11 Million
Q4 2021

Feb 14, 2022

SELL
$10.86 - $13.95 $443,088 - $569,160
-40,800 Reduced 4.2%
929,714 $10.8 Million
Q3 2021

Nov 15, 2021

SELL
$11.92 - $13.92 $12.7 Million - $14.8 Million
-1,064,600 Reduced 52.31%
970,514 $12.7 Million
Q2 2021

Aug 16, 2021

SELL
$10.16 - $13.11 $8.3 Million - $10.7 Million
-817,300 Reduced 28.65%
2,035,114 $26.2 Million
Q1 2021

May 14, 2021

BUY
$9.04 - $11.86 $3.48 Million - $4.57 Million
385,442 Added 15.62%
2,852,414 $31.9 Million
Q4 2020

Feb 16, 2021

SELL
$9.05 - $12.2 $2.79 Million - $3.76 Million
-308,495 Reduced 11.12%
2,466,972 $28.1 Million
Q3 2020

Nov 16, 2020

BUY
$8.99 - $10.74 $7.66 Million - $9.16 Million
852,434 Added 44.33%
2,775,467 $25 Million
Q2 2020

Aug 14, 2020

BUY
$9.14 - $11.97 $3.46 Million - $4.53 Million
378,443 Added 24.5%
1,923,033 $19.8 Million
Q1 2020

May 15, 2020

BUY
$8.58 - $14.01 $13.3 Million - $21.6 Million
1,544,590 New
1,544,590 $15.6 Million
Q2 2019

Aug 14, 2019

SELL
$9.8 - $12.89 $41 Million - $53.9 Million
-4,181,892 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$7.8 - $16.13 $27.8 Million - $57.4 Million
3,560,001 Added 572.45%
4,181,892 $43.3 Million
Q3 2018

Nov 14, 2018

BUY
$14.31 - $17.65 $8.9 Million - $11 Million
621,891 New
621,891 $11.5 Million
Q4 2017

Feb 14, 2018

SELL
$12.16 - $14.58 $31 Million - $37.1 Million
-2,546,095 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$12.07 - $14.87 $30.7 Million - $37.9 Million
2,546,095
2,546,095 $40.2 Million

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $527M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Bridger Management, LLC Portfolio

Follow Bridger Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridger Management, LLC with notifications on news.